SCLERO.ORG
Search
Scleroderma Newsroom
ISN News Manager: Jo Frowde
Autoimmune
Media Stories
Scleroderma
ISN/Website
Autoimmune Archive
We maintain news archives for the most recent 3 years.
2019: Jan Feb Mar Apr May Jun Jul Aug Sep Oct Nov Dec
2020 - 2019 - 2018 - 2017

November 2019 Autoimmune News

Belimumab alters transitional B-cell subset proportions in patients with stable systemic lupus erythematosus. We show that Belimumab-mediated B-cell activating factor depletion reduces the Transitional 2 subset in patients. PubMed, Lupus, 2019 Oct;28(11):1337-1343. (Also see Treatments for Lupus and Clinical Trials)

Clinical evaluation of total and high-avidity (HA) anti-dsDNA antibody assays (EIA) for the diagnosis of systemic lupus erythematosus (SLE). The HA anti-dsDNA EIA kit in association with the total anti-dsDNA kit provided superior performance in SLE diagnosis and monitoring disease activity. PubMed, Lupus, 09/30/2019. (Also see Diagnosis of Lupus)

Risk factors associated with IgA vasculitis with nephritis (VN) (Henoch-Schönlein purpura nephritis) progressing to unfavorable outcomes: A meta-analysis. This meta-analysis showed that older age at onset, lower GFR, initial renal features and renal biopsy with crescentic nephritis were predictive of poor prognosis in children with IgA-VN. PubMed, PLoS One, 2019 Oct 1;14(10):e0223218. (Also see Vasculitis)

Effects of Sarilumab on Rheumatoid Arthritis (RA) as Reported by Patients Using the Rheumatoid Arthritis Impact of Disease (RAID) Scale. Based on the RAID, sarilumab + csDMARD or as monotherapy reduced the effect of RA on patients' lives to a greater extent than placebo + csDMARD or adalimumab monotherapy. PubMed, J Rheumatol, 2019 Oct;46(10):1259-1267. (Also see Treatments for Rheumatoid Arthritis)

Ultrasensitive serum interferon-α quantification during systemic lupus erythematosus (SLE) remission identifies patients at risk for relapse. Direct serum IFN-α assessment with highly sensitive digital immunoassay permits clinicians to identify a subgroup of SLE patients, clinically in remission, but at higher risk of relapse. PubMed, Ann Rheum Dis, 09/30/2019. (Also see Systemic Lupus Erythematosus)

Prevalence of Antiphospholipid Antibodies (aPL) Negativisation in Patients with Antiphospholipid Syndrome: A Long-Term Follow-Up Multicentre Study. aPL negativisation occurred in approximately 9% of patients and negativisation occurred most often in patients who were previously found to be positive for only one aPL. PubMed, Thromb Haemost, 10/06/2019. (Also see Antiphospholipid Syndrome)

Treatment Failures of Direct Oral Anticoagulants (DOACs). Our analysis illustrates that DOACs may fail in the setting of Food and Drug Administration and non-Food and Drug Administration- approved indications. PubMed, Am J Ther, 10/09/2019. (Also see Antiphospholipid Syndrome)

Celiac Disease (CD) and the Microbiome. This review is aimed at summarizing both pre-clinical and clinical evidence addressing the relationship between the intestinal microbiome and CD. PubMed, Nutrients, 2019 Oct 8;11(10). (Also see Celiac Disease)

Type 1 Diabetes Mellitus (T1D) and Celiac Disease (CD): Distinct Autoimmune Disorders That Share Common Pathogenic Mechanisms. Immunogenetics and the environment are closely interrelated in the pathogenesis of T1D and CD. PubMed, Horm Res Paediatr, 2019 Oct 8:1-8. (Also see Celiac Disease and Symptoms and Complications of Diabetes)

Glycemic variability indices can be used to diagnose islet transplantation (IT) success in type 1 diabetic patients. The proposed thresholds allow an easy evaluation of IT success using only continuous glucose monitoring data and may be a clinical tool for the follow-up of transplanted patients. PubMed, Acta Diabetol, 10/10/2019. (Also see Treatments for Diabetes)

Go to Autoimmune News: October 2019
 

We have the world's best supporters! See ISN News.

 

SCLERO.ORG is the world's leading nonprofit for trustworthy research, support, education and awareness for scleroderma and related illnesses. We are a 501(c)(3) U.S.-based public charitable foundation, established in 2002. Meet Our Team. Donations may also be mailed to:

International Scleroderma Network (ISN)
7455 France Ave So #266
Edina, MN 55435-4702 USA
Email [email protected]. Disclaimer. Privacy Policy.
 

The most important thing in the world to know about scleroderma is sclero.org!